SAGE is at the epicenter of today’s CNS innovation – leveraging extensive knowledge and recent advances in chemistry, molecular and in vivo pharmacology, formulation technology and biomarker data to translate scientific breakthroughs into CNS programs that can have a dramatic impact on patient treatment. The company’s proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform focuses on two key, validated nervous system targets: GABAA and NMDA receptors, the primary inhibitory and excitatory receptors that mediate “fast” synaptic transmission in the brain. These targets are critically important and are now better understood than ever before due to decades of biology research, recent scientific progress and SAGE’s own pioneering work.
SAGE’s proprietary PANAM platform yields highly selective and potent positive and negative allosteric modulators of GABAA or NMDA receptors to restore natural balance and normal tone to aberrant neuronal circuits to effectively treat a variety of CNS diseases. Historically it has been challenging to effectively and safely modulate GABAA and NMDA receptors, but SAGE is using “nature as the best starting point” in innovative drug discovery.
Specifically, the company’s PANAM platform is focused on a unique family of small molecule endogenous allosteric modulators that potently and selectively modulate GABAA or NMDA receptors and SAGE is developing proprietary derivatives of these natural products that can more effectively and safely work to restore homeostasis and function in key nervous system pathways.
The SAGE PANAM chemistry platform is driving the development of a new wave of allosteric modulators with unique pharmacology, compelling validation and the potential to make a significant impact for patients with CNS conditions.